Thromboxane A2 receptors. 1995

P V Halushka, and C J Allan, and K L Davis-Bruno
Department of Pharmacology, University of South Carolina, Charleston 29425, USA.

UI MeSH Term Description Entries
D002318 Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. Adverse Cardiac Event,Cardiac Events,Major Adverse Cardiac Events,Adverse Cardiac Events,Cardiac Event,Cardiac Event, Adverse,Cardiac Events, Adverse,Cardiovascular Disease,Disease, Cardiovascular,Event, Cardiac
D003001 Cloning, Molecular The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells. Molecular Cloning
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013928 Thromboxane A2 An unstable intermediate between the prostaglandin endoperoxides and thromboxane B2. The compound has a bicyclic oxaneoxetane structure. It is a potent inducer of platelet aggregation and causes vasoconstriction. It is the principal component of rabbit aorta contracting substance (RCS). Rabbit Aorta Contracting Substance,A2, Thromboxane
D015290 Second Messenger Systems Systems in which an intracellular signal is generated in response to an intercellular primary messenger such as a hormone or neurotransmitter. They are intermediate signals in cellular processes such as metabolism, secretion, contraction, phototransduction, and cell growth. Examples of second messenger systems are the adenyl cyclase-cyclic AMP system, the phosphatidylinositol diphosphate-inositol triphosphate system, and the cyclic GMP system. Intracellular Second Messengers,Second Messengers,Intracellular Second Messenger,Messenger, Second,Messengers, Intracellular Second,Messengers, Second,Second Messenger,Second Messenger System,Second Messenger, Intracellular,Second Messengers, Intracellular,System, Second Messenger,Systems, Second Messenger
D017482 Receptors, Thromboxane Cell surface proteins that bind THROMBOXANES with high affinity and trigger intracellular changes influencing the behavior of cells. Some thromboxane receptors act via the inositol phosphate and diacylglycerol second messenger systems. TP Receptors,Thromboxane Receptors,Receptors, Thromboxanes,TP Receptor,Thromboxane Receptor,Receptor, TP,Receptor, Thromboxane,Receptors, TP,Thromboxanes Receptors
D019204 GTP-Binding Proteins Regulatory proteins that act as molecular switches. They control a wide range of biological processes including: receptor signaling, intracellular signal transduction pathways, and protein synthesis. Their activity is regulated by factors that control their ability to bind to and hydrolyze GTP to GDP. EC 3.6.1.-. G-Proteins,GTP-Regulatory Proteins,Guanine Nucleotide Regulatory Proteins,G-Protein,GTP-Binding Protein,GTP-Regulatory Protein,Guanine Nucleotide Coupling Protein,G Protein,G Proteins,GTP Binding Protein,GTP Binding Proteins,GTP Regulatory Protein,GTP Regulatory Proteins,Protein, GTP-Binding,Protein, GTP-Regulatory,Proteins, GTP-Binding,Proteins, GTP-Regulatory

Related Publications

P V Halushka, and C J Allan, and K L Davis-Bruno
May 2004, Cellular signalling,
P V Halushka, and C J Allan, and K L Davis-Bruno
January 1995, Advances in prostaglandin, thromboxane, and leukotriene research,
P V Halushka, and C J Allan, and K L Davis-Bruno
July 1989, Thrombosis research,
P V Halushka, and C J Allan, and K L Davis-Bruno
February 1991, Clinical science (London, England : 1979),
P V Halushka, and C J Allan, and K L Davis-Bruno
August 2004, Seminars in thrombosis and hemostasis,
P V Halushka, and C J Allan, and K L Davis-Bruno
November 1990, Nihon Jinzo Gakkai shi,
P V Halushka, and C J Allan, and K L Davis-Bruno
August 1997, The Journal of pharmacology and experimental therapeutics,
P V Halushka, and C J Allan, and K L Davis-Bruno
January 1996, Arzneimittel-Forschung,
P V Halushka, and C J Allan, and K L Davis-Bruno
April 2000, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme,
P V Halushka, and C J Allan, and K L Davis-Bruno
January 1998, The Journal of biological chemistry,
Copied contents to your clipboard!